Elranatamab (Genetical Recombination)



Elranatamab is a recombinant bispecific monoclonal antibody against B-cell maturation antigen (BCMA) and CD3ε chain, which is composed of anti-BCMA antibody derived from human IgG2, and anti-CD3ε antibody whose complementarity-determining regions are derived from mouse antibody and other regions are derived from human IgG2. In the anti-BCMA-H-chain, the amino acid residues are substituted at 6 positions (C218E, P223E, D259A, A324S, P325S, L362E). In the anti-CD3ε-H-chain, the amino acid residues are substituted at 7 positions (C224R, E226R, P229R, D265A, A330S, P331S, K409R). Elranatamab is produced in CHO cells. Elranatamab is a glycoprotein (molecular weight: ca. 149,000) composed of an anti-BCMA-H-chain (γ2-chain) consisting of 441 amino acid residues, an anti-CD3ε-H-chain (γ2-chain) consisting of 447 amino acid residues, an anti-BCMA-L-chain (κ-chain) consisting of 215 amino acid residues, and an anti-CD3ε-L-chain (κ-chain) consisting of 219 amino acid residues.

[2408850-14-4]